Kim Margolin

Nov 23, 2024 | mdpi.com | Vivek Podder |Tulika Ranjan |Kim Margolin |Arun Maharaj

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Oct 3, 2024 | mdpi.com | Vivek Podder |Kim Margolin |Vamsidhar Velcheti |Tulika Ranjan

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 17, 2023 | nature.com | Ari Vander Walde |Katie Campbell |Philip O. Scumpia |Alexandra Ikeguchi |Bartosz Chmielowski |Kim Margolin | +3 more

AbstractIn this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.

Jul 18, 2023 | medscape.com | Sapna P. Patel |Kim Margolin

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Sapna P. Patel, MD: Hello. I'm Dr Sapna Patel. Welcome to Medscape's InDiscussion series on melanoma. This is episode number three.

May 26, 2023 | obroncology.com | Allison Warner |Evan J. Lipson |Kim Margolin

Promising results for the use of mRNA vaccines in the treatment of melanoma have patients asking when and if it is an option for them. However, many questions about the “bespoke” approach remain unanswered.